<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976063</url>
  </required_header>
  <id_info>
    <org_study_id>P160917</org_study_id>
    <nct_id>NCT03976063</nct_id>
  </id_info>
  <brief_title>Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation</brief_title>
  <acronym>TOCOPROM</acronym>
  <official_title>Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation: a Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM U1153</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe de Recherche en Obstétrique et Gynécologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal
      morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm premature rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for
      one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and
      increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33
      completed weeks' gestation), expectant management is recommended in the absence of labor,
      chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are
      recommended by international guidelines. However, there is no recommendation regarding
      tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility
      should delay delivery and reduce risks of prematurity and neonatal adverse consequences.
      Likewise, a prolongation of gestation may allow administering a corticosteroids complete
      course that is associated with a two-fold reduction of morbidity and mortality. However,
      tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of
      materno-fetal infection, potentially associated with neonatal death or long-term sequelae,
      including cerebral palsy.

      The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal
      morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perinatal morti-morbidity</measure>
    <time_frame>Up to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Composite outcome including fetal death, neonatal death and/or neonatal severe morbidity (mechanical ventilation ≥ 48 hrs, severe bronchopulmonary dysplasia, severe intraventricular hemorrhage, cystic periventricular leucomalacia, neonatal early-onset sepsis, necrotizing enterocolitis, retinopathy of prematurity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation</measure>
    <time_frame>Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Latency duration (defined as the duration from PPROM to delivery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation</measure>
    <time_frame>Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Pregnancy prolongation beyond 48 hours after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation</measure>
    <time_frame>Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Pregnancy prolongation beyond 1 week after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation</measure>
    <time_frame>Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of gestation</measure>
    <time_frame>Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Delivery after 37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidity</measure>
    <time_frame>During the first 10 days postpartum</time_frame>
    <description>Endometritis, based on clinical diagnosis associating fever (temperature ≥ 38.0°C) with uterine tenderness, purulent or foul-smelling lochia, and in the absence of any other cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal mortality</measure>
    <time_frame>Up to delivery so up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)</time_frame>
    <description>Fetal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Mechanical ventilation ≥ 48 hrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Severe bronchopulmonary dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Severe intraventricular hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Cystic periventricular leucomalacia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to Day 3 after birth.</time_frame>
    <description>Early-onset sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Necrotizing enterocolitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal severe morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Retinopathy of prematurity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>At birth.</time_frame>
    <description>Severe fetal acidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Respiratory distress syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Mild or moderate bronchopulmonary dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>From birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Grades I-II intraventricular hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>From Day 3 after birth to discharge from hospital, with a maximum of 24 weeks after birth.</time_frame>
    <description>Late-onset sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>At 22-26 months of corrected age</time_frame>
    <description>Death between discharge and follow up at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Gross motor impairment among children alive at 2 years of corrected age</measure>
    <time_frame>At 22-26 months of corrected age</time_frame>
    <description>Cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Neurosensory impairment among children alive at 2 years of corrected age</measure>
    <time_frame>At 22-26 months of corrected age</time_frame>
    <description>Visual impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Neurosensory impairment among children alive at 2 years of corrected age</measure>
    <time_frame>At 22-26 months of corrected age</time_frame>
    <description>Hearing impairment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Preterm Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Loading dose: Oral Nifedipine 20 mg LP at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg LP at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)</description>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Nifedipine</intervention_name>
    <description>Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm premature rupture of membranes (PPROM) between 220/7 - 336/7 weeks of
             gestation, as diagnosed by obstetric team

          -  Singleton gestation

          -  Fetus alive at the time of randomization (reassuring fetal heart monitoring)

          -  18 years of age or older

          -  French speaking

          -  Affiliated to social security regime or an equivalent system

          -  Informed consent and signed

        Exclusion Criteria:

          -  PPROM ≥ 24 hours before diagnosis

          -  Ongoing tocolytic treatment at the time of PPROM

          -  Any tocolytic treatment after PPROM diagnosis, including during in utero transfer

          -  Fetal condition contraindicating expectant management including chorioamnionitis,
             placental abruption, intrauterine fetal demise, non-reassuring fetal heart rate at the
             time of randomization

          -  Cervical dilation &gt; 5 cm

          -  Iatrogenic rupture caused by amniocentesis or trophoblast biopsy

          -  Major fetal anomaly

          -  Maternal allergy or contra-indication to Nifedipine or placebo drug components*:

               -  Myocardial infarction

               -  Unstable angina pectoris

               -  Hepatic insufficiency

               -  Cardiovascular shock

               -  Beta blockers

        placebo drug components: lactose monohydrate, colloidal silica, microcrystalline cellulos

          -  Coadministration of diltiazem or rifampicine

          -  Hypotension (systolic pressure &lt; 90 mmHg)

          -  Participation to another interventional research (category 1)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Kayem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM UMR 1153, Obstetrical, Perinatal and PEdiatric Epidemiology (EPOPé) Research Team, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), DHU Risks in Pregnancy, Paris Descartes University, Trousseau University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elsa Lorthe, RM, PhD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM UMR 1153, Obstetrical, Perinatal and PEdiatric Epidemiology (EPOPé) Research Team, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), DHU Risks in Pregnancy, Paris Descartes University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Kayem, MD, PhD</last_name>
    <phone>00 33 1 44 73 51 18</phone>
    <email>gilles.kayem@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly Briand, PhD</last_name>
    <phone>00 33 1 44 38 18 62</phone>
    <email>nelly.briand@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trousseau University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Kayem, MD, PhD</last_name>
      <phone>0033 1 44 73 51 18</phone>
      <email>gkayem@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Clémence Cabanne, RM</last_name>
      <phone>0033 1 71 73 86 95</phone>
      <email>clemencecabanne.tocoprom@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mackeen AD, Seibel-Seamon J, Muhammad J, Baxter JK, Berghella V. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2014 Feb 27;(2):CD007062. doi: 10.1002/14651858.CD007062.pub3. Review.</citation>
    <PMID>24578236</PMID>
  </reference>
  <reference>
    <citation>Lorthe E, Goffinet F, Marret S, Vayssiere C, Flamant C, Quere M, Benhammou V, Ancel PY, Kayem G. Tocolysis after preterm premature rupture of membranes and neonatal outcome: a propensity-score analysis. Am J Obstet Gynecol. 2017 Aug;217(2):212.e1-212.e12. doi: 10.1016/j.ajog.2017.04.015. Epub 2017 Apr 13.</citation>
    <PMID>28412086</PMID>
  </reference>
  <reference>
    <citation>Couteau C, Haumonté JB, Bretelle F, Capelle M, D'Ercole C. [Management of preterm and prelabour rupture of membranes in France]. J Gynecol Obstet Biol Reprod (Paris). 2013 Feb;42(1):21-8. doi: 10.1016/j.jgyn.2012.10.008. Epub 2012 Nov 24. French.</citation>
    <PMID>23182704</PMID>
  </reference>
  <reference>
    <citation>Schmitz T, Sentilhes L, Lorthe E, Gallot D, Madar H, Doret-Dion M, Beucher G, Charlier C, Cazanave C, Delorme P, Garabédian C, Azria E, Tessier V, Sénat MV, Kayem G. Preterm premature rupture of the membranes: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2019 May;236:1-6. doi: 10.1016/j.ejogrb.2019.02.021. Epub 2019 Mar 2. Review.</citation>
    <PMID>30870741</PMID>
  </reference>
  <reference>
    <citation>Flenady V, Wojcieszek AM, Papatsonis DN, Stock OM, Murray L, Jardine LA, Carbonne B. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev. 2014 Jun 5;(6):CD002255. doi: 10.1002/14651858.CD002255.pub2. Review.</citation>
    <PMID>24901312</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preterm premature rupture of membranes</keyword>
  <keyword>Tocolysis</keyword>
  <keyword>Nifedipine</keyword>
  <keyword>Latency</keyword>
  <keyword>Neonatal outcome</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

